Corina Kohler

Corina Kohler

Auto-generated profile, based on publicly available information

Corina Kohler

Laboratory for Gynecological Oncology, Department of Biomedicine, Women’s Hospital, University of Basel, Hebelstrasse 20, Room 420, Basel, CH 4031, Switzerland

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2009 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
CKCorina Kohler
Corina Kohler
RRRamin Ramin Radpour
Ramin Ramin Radpour
ZBZeinab Barekati
Zeinab Barekati
RAReza Asadollahi
Reza Asadollahi
JBJohannes Bitzer
Johannes Bitzer
XZXiao Yan Zhong
Xiao Yan Zhong
Background: With the aim to simplify cancer management, cancer research lately dedicated itself more and more to discover and develop non-invasive biomarkers. In this connection, circulating cell-free DNA (ccf DNA) seems to be a promising candidate. Altered levels of ccf nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) have been found in several cancer types and might have a diagnostic value. Methods: Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls. To evaluate the applicability of plasma ccf nDNA and mtDNA as a biomarker for distinguishing between the three study-groups we performed ROC (Receiver Operating Characteristic) curve analysis. We also compared the levels of both species in the cancer group with clinicopathological parameters. Results: While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022). The level of ccf nDNA was also associated with tumor-size (2 cm<5 cm; 2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034). Using ROC curve analysis, we were able to distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker (cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%; specificity: 87%; P < 0.001). Conclusion: Our data suggests that nuclear and mitochondrial ccf DNA have potential as biomarkers in breast tumor management. However, ccf nDNA shows greater promise regarding sensitivity and specificity.

21 December 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
PXPeng Xia
Peng Xia
HAhanxiang An
hanxiang An
CDCheng-Xue Dang
Cheng-Xue Dang
RRRamin Ramin Radpour
Ramin Ramin Radpour
CKCorina Kohler
Corina Kohler
XZXiao Yan Zhong
Xiao Yan Zhong
Background: Alterations of mitochondrial DNA (mtDNA) have been implicated in carcinogenesis. We developed an accurate multiplex quantitative real-time PCR for synchronized determination of mtDNA and nuclear DNA (nDNA). We sought to investigate whether mtDNA content in the peripheral blood of breast cancer patients is associated with clinical and pathological parameters. Methods: Peripheral blood samples were collected from 60 patients with breast cancer and 51 age-matched healthy individuals as control. DNA was extracted from peripheral blood for the quantification of mtDNA and nDNA, using a one-step multiplex real-time PCR. A FAM labeled MGB probe and primers were used to amplify the mtDNA sequence of the ATP 8 gene, and a VIC labeled MGB probe and primers were employed to amplify the glyceraldehyde-3-phosphate-dehydrogenase gene. mtDNA content was correlated with tumor stage, menstruation status, and age of patients as well as lymph node status and the expression of estrogen receptor (ER), progesterone receptor (PR) and Her-2/neu protein. Results: The content of mtDNA in stage I breast cancer patients was significantly lower than in other stages (overall P = 0.023). Reduced mtDNA was found often in post menopausal cancer group (P = 0.024). No difference in mtDNA content, in regards to age (p = 0.564), lymph node involvement (p = 0.673), ER (p = 0.877), PR (p = 0.763), and Her-2/neu expression (p = 0.335), was observed. Conclusion: Early detection of breast cancer has proved difficult and current detection methods are inadequate. In the present study, decreased mtDNA content in the peripheral blood of patients with breast cancer was strongly associated with stage I. The use of mtDNA may have diagnostic value and further studies are required to validate it as a potential biomarker for early detection of breast cancer.

Verified
Journal Article
Open access
PDF file
FCFeng-Feng Cai
Feng-Feng Cai
CKCorina Kohler
Corina Kohler
BZBei Zhang
Bei Zhang
MWMing-Hong Wang
Ming-Hong Wang
WCWei-Jie Chen
Wei-Jie Chen
XZXiao-Yan Zhong
Xiao-Yan Zhong
Both genetic and epigenetic alterations can control the progression of cancer. Genetic alterations are impossible to reverse, while epigenetic alterations are reversible. This advantage suggests that epigenetic modifications should be preferred in therapy applications. DNA methyltransferases and histone deacetylases have become the primary targets for studies in epigenetic therapy. Some DNA methylation inhibitors and histone deacetylation inhibitors are approved by the US Food and Drug Administration as anti-cancer drugs. Therefore, the uses of epigenetic targets are believed to have great potential as a lasting favorable approach in treating breast cancer.

1 August 2011
Verified
Journal Article
Closed access
CKCorina Kohler
Corina Kohler
ZBZeinab Barekati
Zeinab Barekati
RRRamin Ramin Radpour
Ramin Ramin Radpour
XZXiao Yan Zhong
Xiao Yan Zhong

1 January 2010
Verified
Journal Article
Closed access
BZBei Zhang
Bei Zhang
ZBZeinab Barekati
Zeinab Barekati
CKCorina Kohler
Corina Kohler
RRRamin Ramin Radpour
Ramin Ramin Radpour
RAReza Asadollahi
Reza Asadollahi
XZXiao Yan Zhong
Xiao Yan Zhong

1 December 2011
Verified
Journal Article
Closed access
FCFeng Feng Cai
Feng Feng Cai
CKCorina Kohler
Corina Kohler
BZBei Zhang
Bei Zhang
WCWei Jie Chen
Wei Jie Chen
ZBZeinab Barekati
Zeinab Barekati
XZXiao Yan Zhong
Xiao Yan Zhong